Patents Assigned to Scil Proteins GmbH
-
Patent number: 9492572Abstract: The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.Type: GrantFiled: June 15, 2012Date of Patent: November 15, 2016Assignee: Scil Proteins GmbHInventors: Joerg Nerkamp, Eva Bosse-Doenecke, Arnd Steuernagel, Ulrike Fiedler, Markus Fiedler
-
Publication number: 20150183846Abstract: The present invention relates to fusion proteins in which a biologically active moiety is linked to a targeting domain. The invention specifically concerns fusion proteins comprising single-chain (sc) TNFalpha monomers as biologically active moiety and a specific targeting domain, preferably fusion proteins comprising at least three scTNFalpha monomers and modified hetero-dimeric ubiquitin proteins with high affinity to target molecules (Affilin® molecules). The invention further relates to these fusion proteins for use in medicine, in particular in the treatment of cancer. The invention is further directed to pharmaceutical compositions comprising such fusion proteins in combination with chemotherapeutics agents.Type: ApplicationFiled: June 13, 2013Publication date: July 2, 2015Applicant: Scil Proteins GmbHInventors: Christian Lange, Manja Gloser, Susan Lorey, Markus Fiedler
-
Patent number: 8921304Abstract: The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.Type: GrantFiled: December 14, 2010Date of Patent: December 30, 2014Assignee: Scil Proteins GmbHInventors: Arnd Steuernagel, Erik Fiedler, Markus Fiedler, Anja Kunert, Joerg Nerkamp, Thomas Goettler, Manja Gloser, Ilka Haenssgen
-
Publication number: 20140219959Abstract: The present invention relates to fusion proteins in which a pharmaceutically active component is fused to an antibody mimetic. The invention specifically concerns fusion proteins comprising interferons or biologically active muteins thereof and modified hetero-dimeric ubiquitin proteins as specific targeting domain. The invention further relates to these fusion proteins for use in medicine, in particular for use in the treatment of cancer or infectious diseases. The invention is further directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with such fusion proteins, and in combination with cancer therapeutic agents. Moreover, the invention relates to a method for the generation of said fusion proteins.Type: ApplicationFiled: June 15, 2012Publication date: August 7, 2014Applicant: Scil Proteins GmbHInventors: Joerg Nerkamp, Ilka Haenssgen, Christian Lange, Manja Gloser, Arnd Steuemagel, Antje Parther
-
Patent number: 8790895Abstract: The invention relates to modified proteins of the superfamily of “ubiquitin-like proteins”, proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.Type: GrantFiled: November 18, 2005Date of Patent: July 29, 2014Assignee: Scil Proteins GmbHInventors: Markus Fiedler, Ulrike Fiedler, Rainer Rudolph
-
Patent number: 8791238Abstract: The invention relates to modified proteins of the superfamily of “ubiquitin-like proteins”, proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.Type: GrantFiled: February 29, 2008Date of Patent: July 29, 2014Assignee: Scil Proteins GmbHInventors: Markus Fiedler, Ulrike Fiedler, Rainer Rudolph
-
Patent number: 8748351Abstract: The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided.Type: GrantFiled: December 14, 2010Date of Patent: June 10, 2014Assignee: Scil Proteins GmbHInventors: Anja Kunert, Jörg Narkamp, Arnd Steuernagel, Markus Fiedler, Erik Fiedler, Thomas Göttler
-
Publication number: 20140127129Abstract: The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.Type: ApplicationFiled: June 15, 2012Publication date: May 8, 2014Applicant: Scil Proteins GmbHInventors: Joerg Nerkamp, Eva Bosse-Doenecke, Arnd Steuernagel, Ulrike Fiedler, Markus Fiedler
-
Patent number: 8629088Abstract: The present invention concerns a protein mixture comprising at least a first fusion protein comprising a protein or protein fragment, and an interaction domain and a protein translocation sequence, which effects that the fusion protein upon expression in a bacterium is translocated through the cytoplasmic membrane in an essentially unfolded state and at least a second fusion protein comprising a protein or protein fragment, and an interaction domain and a protein translocation sequence which effects that the fusion protein is translocated through the cytoplasmic membrane upon expression in a bacterium in an essentially folded state, wherein the interaction domain of the first protein can bind to those of the second protein.Type: GrantFiled: August 31, 2011Date of Patent: January 14, 2014Assignee: Scil Proteins GmbHInventor: Matthias Paschke
-
Patent number: 8592144Abstract: The present invention describes novel beta-sheet proteins having specific binding properties and catalytic properties and also methods for preparing these proteins.Type: GrantFiled: January 23, 2007Date of Patent: November 26, 2013Assignee: Scil Proteins GmbHInventors: Ulrike Fiedler, Rainer Rudolph
-
Patent number: 8592179Abstract: The present invention is directed to a method for the generation of binding proteins derived from the protein super-family of ubiquitin like proteins with modifications in their alpha helical region as well as to a protein obtainable by said method. Furthermore, the invention provides the use of a protein for the specific recognition, binding and neutralization of a predescribed target molecule, for the detection, quantitative determination, separation and/or for the isolation of a corresponding binding partner and the use of a protein of the invention, for diagnosis, prophylaxis and treatment of diseases in which the corresponding binding partner is directly or indirectly involved.Type: GrantFiled: November 15, 2007Date of Patent: November 26, 2013Assignee: Scil Proteins GmbHInventors: Michael Schraeml, Erik Fiedler
-
Patent number: 8501439Abstract: The invention relates to a method for producing biologically active ?-NGF from the proform proNGF. After expressing the proform of the ?-NGF in a prokaryotic host cell, the recombinant protein is isolated in the form of insoluble inactive aggregates (inclusion bodies). After the solubilization thereof in a strong denaturing agent and the subsequent conversion thereof into the natural conformation, which is determined by the disulfide bridges present in the natural ?-NGF, biologically active ?-NGF is obtained by subsequently splitting-off the prosequence.Type: GrantFiled: April 22, 2010Date of Patent: August 6, 2013Assignee: Scil Proteins GmbHInventors: Anke Rattenholl, Adelbert Grossmann, Elisabeth Schwarz, Rainer Rudolph
-
Publication number: 20130183265Abstract: The present invention relates to the human and murine melanoma inhibitory activity protein-2 (MIA-2) and to the nucleic acids encoding said proteins including a method for producing such proteins by recombinant techniques. The invention also relates to methods for utilizing such proteins for tissue regeneration, tumor treatment including to control the proliferation and differentiation of liver cells in vivo and in vitro. The invention further relates to diagnostic assays including the human and murine antibodies or aptamers and their use in therapy and diagnosis. Further it relates to diagnostic assays applying specific primers for the diagnostic of liver disease.Type: ApplicationFiled: October 12, 2012Publication date: July 18, 2013Applicant: SCIL PROTEINS GMBHInventor: Scil Proteins GmbH
-
Patent number: 8426357Abstract: The present invention is directed to a multimeric agent and a multimeric conjugate formed from this multimeric agent and a biologically active agent. Said multimeric conjugates have a longer life time in vivo and an increased avidity compared to the unmodified biologically agent. The present invention is further directed to a pharmaceutical or diagnostic composition containing said conjugate as well as to a method of its production. The invention additionally provides the use of said conjugates for the detection, determination, separation and/or isolation of a specific binding partner and for the diagnosis, prophylaxis and treatment of diseases in which the specific binding partner is directly or indirectly involved.Type: GrantFiled: February 11, 2008Date of Patent: April 23, 2013Assignees: celares GmbH, Scil Proteins GmbHInventors: Ralf Kraehmer, Frank Leenders, Erik Fiedler, Thomas Hey, Ulrike Fiedler, Markus Fiedler
-
Publication number: 20130052715Abstract: The invention relates to a method for producing folded prethrombin, wherein inclusion bodies, which contain unfolded prethrombin or a derivative thereof, are solubilized in a solubilization buffer containing at least one chaotropic compound and at least one organic disulfide compound. The invention further relates to methods for producing thrombin and a-thrombin and derivatives thereof. The invention also relates to solutions that contain folded proteins, which can be produced by the methods according to the invention.Type: ApplicationFiled: April 20, 2011Publication date: February 28, 2013Applicant: Scil Proteins GmbHInventors: Andreas Anton, Arndt Dietrich, Jochen Koetter, Joerg Schaeffner
-
Patent number: 8318671Abstract: The invention relates to a method for producing biologically active ?-NGF from the proform proNGF. After expressing the proform of the ?-NGF in a prokaryotic host cell, the recombinant protein is isolated in the form of insoluble inactive aggregates (inclusion bodies). After the solubilization thereof in a strong denaturing agent and the subsequent conversion thereof into the natural conformation, which is determined by the disulfide bridges present in the natural ?-NGF, biologically active ?-NGF is obtained by subsequently splitting-off the prosequence.Type: GrantFiled: October 11, 1999Date of Patent: November 27, 2012Assignee: Scil Proteins GmbHInventors: Anke Rattenholl, Adelbert Grossmann, Elisabeth Schwarz, Rainer Rudolph
-
Publication number: 20120015819Abstract: The present invention concerns a protein mixture comprising at least a first fusion protein comprising a protein or protein fragment, and an interaction domain and a protein translocation sequence, which effects that the fusion protein upon expression in a bacterium is translocated through the cytoplasmic membrane in an essentially unfolded state and at least a second fusion protein comprising a protein or protein fragment, and an interaction domain and a protein translocation sequence which effects that the fusion protein is translocated through the cytoplasmic membrane upon expression in a bacterium in an essentially folded state, wherein the interaction domain of the first protein can bind to those of the second protein.Type: ApplicationFiled: August 31, 2011Publication date: January 19, 2012Applicant: SCIL PROTEINS GmbHInventor: Matthias PASCHKE
-
Patent number: 7838629Abstract: The present invention relates to conjugates containing a covalent linkage between one or more polypeptide molecules based on gamma-crystallin or ubiquitin and one or more functional components. Furthermore, the present invention relates to a method for the preparation of such a conjugate as well as to the use of the conjugate in diagnostics, therapy and chromatography.Type: GrantFiled: April 4, 2007Date of Patent: November 23, 2010Assignee: Scil Proteins GmbHInventors: Erik Fiedler, Hilmar Ebersbach, Thomas Hey, Ulrike Fiedler
-
Patent number: 7601803Abstract: The present invention describes novel beta-sheet proteins having specific binding properties and catalytic properties and also methods for preparing these proteins.Type: GrantFiled: July 13, 2000Date of Patent: October 13, 2009Assignee: Scil Proteins GmbHInventors: Ulrike Fiedler, Rainer Rudolph, Gerald Boehm, Carola Reimann
-
Publication number: 20080171851Abstract: The invention relates to modified proteins of the superfamily of “ubiquitin-like proteins”, proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.Type: ApplicationFiled: February 29, 2008Publication date: July 17, 2008Applicant: Scil Proteins GmbHInventors: Markus Fiedler, Ulrike Fiedler, Rainer Rudolph